

Supplementary Table 1. Baseline patient characteristics among patients treated with continuous DAP, continuous LZD, or sequential LZD-DAP treatment for VREF-BSI

Characteristic (N=2,630)	DAP (n=1,055)	LZD (n=1,348)	LZD to DAP (n=227)	P- value
Age ≥ 65 years, n (%)	480 (45.5)	737 (54.7)	103 (45.4)	<0.001
Male gender, n (%)	1027 (97.3)	1319 (97.8)	218 (96.0)	0.251
Concomitant pneumonia ^a , n (%)	34 (3.2)	65 (4.8)	21 (9.3)	<0.001
Facility complexity level, n (%)	---	---	---	---
1a (most complex)	784 (74.3)	787 (58.4)	148 (85.2)	<0.001
1b	178 (16.9)	348 (25.8)	54 (23.8)	<0.001
1c	80 (7.6)	164 (12.2)	22 (9.7)	0.001
2	12 (1.1)	37 (2.7)	2 (0.9)	0.009
3 (least complex)	1 (0.1)	12 (0.9)	1 (0.4)	0.029
Year of infection, n (%)	---	---	---	---
2004	10 (0.9)	180 (13.4)	7 (3.1)	<0.001
2005	35 (3.3)	219 (16.2)	17 (7.5)	<0.001
2006	64 (6.1)	222 (16.5)	24 (10.9)	<0.001
2007	85 (8.1)	179 (13.3)	26 (11.5)	<0.001
2008	132 (12.5)	173 (12.8)	37 (16.3)	0.295
2009	125 (11.8)	107 (7.9)	31 (13.7)	0.001
2010	146 (13.8)	65 (4.8)	29 (12.8)	<0.001
2011	154 (14.6)	78 (5.8)	20 (8.8)	<0.001
2012	128 (12.1)	59 (4.4)	20 (8.8)	<0.001
2013	97 (9.2)	42 (3.1)	8 (3.5)	<0.001
2014	79 (7.5)	24 (1.8)	8 (3.5)	<0.001
Infectious diseases consult ^b , n (%)	571 (54.1)	548 (40.7)	121 (53.3)	<0.001
Source of VRE-BSI, n (%)	---	---	---	---
Genitourinary only	134 (12.7)	174 (12.9)	29 (12.8)	0.989
Abdominal/gastrointestinal only	52 (4.9)	52 (3.7)	7 (3.1)	0.419
Line-associated only	96 (9.1)	177 (13.1)	21 (9.3)	0.005
Endocarditis/cardiac device only	99 (9.4)	97 (7.2)	25 (11.0)	0.053
Wound/Bone only	26 (2.5)	31 (2.3)	8 (3.5)	0.477
Multiple	158 (15.0)	175 (13.0)	54 (23.8)	<0.001
Unknown	490 (46.4)	642 (47.6)	83 (36.5)	0.006
Previous VRE stool colonization ^c , n (%)	122 (11.6)	128 (9.5)	18 (7.9)	0.125
Time-to- treatment (days) ^d , median (IQR)	3 (2-4)	3 (2-4)	3 (1-3)	<0.001
Concomitant β-lactam treatment ^e , n (%)	812 (77.0)	1086 (80.6)	203 (89.4)	<0.001
Concomitant aminoglycoside treatment ^f , n (%)	120 (11.4)	155 (11.5)	39 (17.2)	0.039
Intensive care unit admission, n (%)	317 (30.0)	455 (33.8)	78 (34.4)	0.123
Any malignancy, n (%)	421 (39.9)	399 (29.6)	73 (32.2)	<0.001
Solid tumor	262 (24.9)	259 (19.2)	42 (18.5)	0.002
Hematologic	286 (27.1)	207 (15.4)	42 (18.5)	<0.001
Solid organ transplant recipient, n (%)	39 (3.7)	33 (2.4)	13 (5.7)	0.019
Kidney	9 (0.9)	10 (0.7)	5 (2.2)	0.098
Liver	28 (2.7)	22 (1.6)	8 (3.5)	0.088
Lung	2 (0.2)	0 (0.0)	1 (0.4)	0.123
Heart	2 (0.2)	2 (0.1)	0 (0.0)	0.801
Charlson comorbidity index, median (IQR)	7 (4-9)	7 (4-9)	7 (4-10)	0.176
Moderate-severe renal disease	569 (53.9)	686 (50.9)	122 (53.7)	0.303
Severe liver disease, n (%)	130 (12.3)	97 (7.2)	37 (16.3)	<0.001
Metastatic solid tumor, n (%)	128 (12.1)	167 (12.4)	18 (7.9)	0.151
HIV-positive, n (%)	29 (2.7)	39 (2.9)	7 (3.1)	0.909
Neutropenia, n (%)	186 (17.6)	82 (6.8)	24 (10.6)	<0.001
Thrombocytopenia, n (%)	222 (21.0)	122 (9.1)	31 (13.7)	<0.001
APACHE II, median (IQR)	14 (10-17)	14 (10-18)	15 (12-19)	0.013

VRE-BSI, vancomycin-resistant *Enterococcus faecium* bloodstream infection; LZD, linezolid (continuous); DAP, daptomycin (continuous); LZD-DAP, sequential linezolid to daptomycin therapy; HIV, human immunodeficiency virus; APACHE II, Acute Physiology and Chronic Health Evaluation II

Categorical variables compared by chi-square or Fisher's exact test

Continuous variables compared by Mann-Whitney *U* test

^a Within 72 hours of index culture

^b Within 48 hours of treatment

^c Positive VRE stool screening within preceding 90 days; negative culture data not available

^d Time from index VRE blood culture to first dose of daptomycin or linezolid

^e At least 1 dose of the following: ampicillin, ampicillin/sulbactam, ticarcillin/clavulanate, aztreonam, cefazolin, cefotaxime, ceftazidime, ceftriaxone, cefepime, ertapenem, meropenem, doripenem, imipenem/cilastatin, or piperacillin/tazobactam

^f At least 1 dose of the following: amikacin, gentamicin, or tobramycin